Compare +50 FDA STeP Providers
The FDA Safer Technologies Program (STeP) is designed for devices that are expected to significantly improve the safety of currently available treatments for diseases or conditions that are less serious than those covered under Breakthrough Device designation. This page helps you compare +50 providers and select support that matches your evidence maturity, team bandwidth, and timeline goals.
Need planning support before provider outreach?
Use our calculators first so your scope, timeline, and budget assumptions are consistent before you interview external teams.
Open STeP Eligibility CalculatorWhat Strong STeP Providers Actually Do
High-quality STeP support is less about generic “regulatory writing” and more about connecting intended use, risk reduction claims, and data strategy to the right FDA interaction model. A capable team should be able to explain where STeP creates practical review efficiency and where it does not. They should also map your STeP strategy to the likely downstream pathway (for example, De Novo or 510(k)), because weak alignment at this stage causes expensive rewrites later.
Look for providers that can document a clear evidence ladder, including bench, human factors, software, cybersecurity, and postmarket assumptions. Ask for sample deliverables showing decision logs and traceability between safety-improvement claims and objective endpoints. If a provider cannot show this structure, you may get polished documents that still trigger avoidable FDA questions.
Provider Comparison Framework
Use this framework when evaluating any STeP provider group.
- Program fit: Can they explain STeP eligibility boundaries with references to FDA language, not just sales positioning?
- Evidence translation: Do they convert engineering evidence into a reviewer-friendly clinical and safety narrative?
- Submission architecture: Can they structure content so later Q-Sub, De Novo, or 510(k) modules reuse core material?
- Cross-functional depth: Do they coordinate RA, quality, clinical, software, and human factors in one plan?
- Delivery controls: Do they work with milestone gates, review checklists, and measurable acceptance criteria?
Representative Provider Types (Compare +50)
Most teams evaluate a mix of providers across these categories. The examples below are category templates, not endorsements.
Category A: Strategy-Led Regulatory Firms
Best for teams that need endpoint strategy and interaction planning before major verification spend.
STeP fit assessment Q-Sub planning eSTAR readinessCategory B: Full-Service Submission Teams
Best for teams with limited internal writing bandwidth and multi-workstream coordination needs.
Submission assembly Technical editing AI-response supportCategory C: Clinical + Biostats Specialists
Best when your safety-improvement thesis depends on endpoint rigor, protocol logic, or comparative analyses.
Study design Endpoint definition Bias controlCategory D: Software/Cybersecurity Focused Groups
Best for digital and connected devices that require robust threat modeling and lifecycle controls.
SBOM strategy Threat modeling Secure update postureKeyword intent note: This directory is aligned to high-intent search patterns such as “FDA STeP providers,” “STeP eligibility support,” “Safer Technologies Program consultant,” and “STeP submission help,” then mapped to practical selection criteria.
How To Use This Directory With Cruxi Tools
Use the workflow below before provider calls:
- Run the STeP eligibility calculator to baseline your probable fit and evidence gaps.
- Run the STeP timeline calculator to estimate interaction windows and bottlenecks.
- Run the STeP resource budget calculator to define scope and internal FTE constraints.
- Share all three outputs with candidate providers and request a redline plan, not a generic proposal deck.
Related Pages
If your product may route into 510(k), review the 510(k) checklist, eSTAR guide, and fees and timeline page to avoid contradictory assumptions between early STeP positioning and later submission modules.